Navigation Links
Cynvenio and CollabRx Announce Partnership for Cancer Molecular Diagnostics
Date:12/11/2013

Westlake Village, CA (PRWEB) December 11, 2013

Cynvenio, a cancer diagnostics company focused on transforming cancer treatment and management through the genomic analysis of tumor cells in blood, today announced a multi-year agreement with CollabRx, Inc., a data analytics company focused on informing clinical decision making in molecular medicine, to offer clinical actionable reports built from CollabRx data and information services with Cynvenio genomic tests.

Under this agreement, Cynvenio will access multiple CollabRx products including the Genetic Variant Annotation (GVA) ServiceTM to offer clinically relevant data and reporting solutions with Cynvenio’s ClearID Breast Cancer and LiquidBiopsy® genomic testing services. ClearID is a monitoring test for breast cancer survivors at high risk of disease recurrence. The ClearID blood test analyzes circulating tumor cells for cancer-associated genomic mutations which can be used to characterize disease status and available treatment options. Clinicians and researchers ordering genomic tests from Cynvenio will now have the option to also choose GVA-based reporting on identified mutations that includes a summary of the clinical evidence for treatment planning, approved targeted therapies, relevant clinical trials for investigational therapies, and additional references for further research.

"A contextualized interpretation of sequencing results is required to make the results of genomic tests actionable for physicians providing highly personalized cancer treatments to their patients," said André de Fusco, CEO of Cynvenio. "CollabRx has developed a scalable process and software platform to provide key elements of the reporting solution that Cynvenio provides to aid physicians in the clinical interpretation of tumor-specific molecular profiles. We are pleased to be able to include GVA with our molecular testing services."

"Cynvenio has introduced an innovative blood test to help monitor for disease in breast cancer survivors at high risk for recurrence,” said Thomas Mika, Chairman, President & CEO of CollabRx. "Their approach of combining the detection of circulating tumor cells with genomic analysis is important for the early detection of cancer, choice of therapy, and ultimately to achieve the best possible clinical outcomes for breast cancer patients. We chose to extend CollabRx expertise and services to ‘liquid biopsy’ for the first time with Cynvenio because they are at the forefront of the sector with a strong focus on advancing personalized medicine in cancer."

Cynvenio and CollabRx representatives will be on hand to discuss and demonstrate the ClearID Breast Cancer test with the GVA reporting service this week at the San Antonio Breast Cancer Symposium, a leading forum for clinical oncologists specializing in the treatment of breast cancer that is being held from December 10-14 in San Antonio, Texas.

The companion announcement from CollabRx is available on: http://www.collabrx.com.

About Cynvenio Biosystems, Inc.

Cynvenio is a cancer diagnostics company focused on transforming cancer treatment and management through the molecular analysis of tumor biomarkers in the bloodstream. This expertise has resulted in two distinct product offerings: ClearID Breast Cancer monitoring program and LiquidBiopsy. ClearID Breast Cancer, designed for use by patients and their physicians, is a cancer detection and monitoring program that assesses 50 oncogenes for more than 4,500 genetic mutations using next-generation sequencing. This test and real-time molecular analysis provide actionable information that can inform treatment considerations and help improve treatment outcomes. LiquidBiopsy is designed for industry and academic researchers to identify the presence of tumor-cell genetic mutations in whole blood. Founded in 2008, Cynvenio is headquartered in Westlake Village, Calif. (Los Angeles). For more information visit http://www.cynvenio.com. LiquidBiopsy® is a registered trademark of Cynvenio Biosystems, Inc.

About CollabRx

CollabRx, Inc. is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world’s knowledge on genomics-based medicine with specific insights from the nation’s top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.

Read the full story at http://www.prweb.com/releases/2013/12/prweb11412224.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Cynvenio Biosystems Receives CLIA Certification for its Genomic Sequencing Laboratory
2. Cynvenio Biosystems to Present Clinical Data on Mutational Analysis of LiquidBiopsy® Tumor Samples at the 2013 ASCO Annual Meeting
3. Washington SmartCEO Announces Portal Solutions as Future 50 Award Winner
4. Barnet Dulaney Perkins Eye Center Regrets to Announce the Passing of David Dulaney, MD
5. InterMune Announces Support of The Pulmonary Fibrosis Foundation Care Center Network and Patient Registry Initiative
6. Cardia 7 Pleased to Announce its Cholesterol Reducing Purified Omega 7
7. Excelera Corp. Announces Commitments by National Leaders
8. Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic Program For Treatment Of Sickle Cell Disease And Beta-Thalassemia At American Society Of Hematology Meeting
9. MiMedx Group Announces Proposed Public Offering of Common Stock
10. Intra-Cellular Therapies Announces Positive Topline Phase II Clinical Results of ITI-007 for the Treatment of Schizophrenia
11. Prova Education Announces Expansion of Its Nationwide Medical Education Series “From Guideline to Practice: Managing Challenging Cases in Primary Care”
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):